Purpose Peripheral T-cell lymphomas (PTCLs) have aggressive clinical behavior. We have previously shown that event-free survival (EFS) at 24 months (EFS24) is a clinically useful end point in diffuse large B-cell lymphoma. Here, we assess EFS24 and subsequent overall survival (OS) in large, multinational PTCL cohorts. Patients and Methods Patients with systemic PTCL newly diagnosed from 2000 to 2012 and treated with curative intent were included from the United States and Sweden (initial cohorts) and from Canada (replication cohort). EFS was defined as time from date of diagnosis to progression after primary treatment, retreatment, or death. Subsequent OS was measured after achieving EFS24 or from the time of progression if it occurred within 24 months. OS rates were compared with the age-, sex-, and country-matched general population. Results Seven hundred seventy-five patients were included in the study (the median age at diagnosis was 64 years; 63% were men). Results were similar in the initial and replication cohorts, and a combined analysis was undertaken. Sixty-four percent of patients progressed within the first 24 months and had a median OS of only 4.9 months (5-year OS, 11%). In contrast, median OS after achieving EFS24 was not reached (5-year OS, 78%), although relapses within 5 years of achieving EFS24 occurred in 23% of patients. Superior outcomes after achieving EFS24 were observed in younger patients (≤ 60 years of age: 5-year OS, 91%). Conclusion EFS24 stratifies subsequent outcome in PTCL. Patients with PTCL with primary refractory disease or early relapse have extremely poor survival. However, more than one third of patients with PTCL remain in remission 2 years after diagnosis with encouraging subsequent OS, especially in younger patients. These marked differences in outcome suggest that EFS24 has utility for patient counseling, study design, and risk stratification in PTCL.

中文翻译：

---

外周 T 细胞淋巴瘤 24 个月无事件生存率和后续生存率的国际评估

目的外周 T 细胞淋巴瘤 (PTCL) 具有侵袭性的临床行为。我们之前已经表明，24 个月的无事件生存期 (EFS) (EFS24) 是弥漫性大 B 细胞淋巴瘤的临床有用终点。在这里，我们评估了大型跨国 PTCL 队列中的 EFS24 和随后的总生存期 (OS)。患者和方法 2000 年至 2012 年间新诊断的全身性 PTCL 患者并接受了治愈性治疗，包括来自美国和瑞典（初始队列）和加拿大（复制队列）的患者。EFS 被定义为从诊断之日到初次治疗、再治疗或死亡后进展的时间。在达到 EFS24 后或从进展时间（如果发生在 24 个月内）测量随后的 OS。将 OS 率与年龄、性别和国家匹配的一般人群进行比较。结果 研究中包括 775 名患者（诊断时的中位年龄为 64 岁；63% 为男性）。结果在初始和复制队列中相似，并进行了联合分析。64% 的患者在前 24 个月内出现进展，中位 OS 仅为 4.9 个月（5 年 OS，11%）。相比之下，虽然 23% 的患者在达到 EFS24 后 5 年内复发，但并未达到达到 EFS24 后的中位 OS（5 年 OS，78%）。在年轻患者（≤ 60 岁：5 年 OS，91%）中观察到达到 EFS24 后的优异结果。结论 EFS24 对 PTCL 的后续结果进行分层。原发性难治性或早期复发的 PTCL 患者生存率极低。然而，超过三分之一的 PTCL 患者在诊断后 2 年仍处于缓解状态，随后的 OS 令人鼓舞，尤其是在年轻患者中。结果的这些显着差异表明 EFS24 可用于 PTCL 的患者咨询、研究设计和风险分层。